Deximune 25, 50, 100 mg

/ Dexcel

The dose ranges given for oral administration are intended to serve as guidelines only.
The daily doses of Deximune should always be given in two divided doses equally distributed throughout the day. It is recommended that Deximune be administered on a consistent schedule with regard to time of day and in relation to meals.
Deximune should only be prescribed by, or in close collaboration with, a physician with experience of immunosuppressive therapy and/or organ transplantation.
Transplantation
Solid organ transplantation
Treatment with Deximune should be initiated within 12 hours before surgery at a dose of 10 to 15 mg/kg given in 2 divided doses. This dose should be maintained as the daily dose for 1 to 2 weeks post-operatively, being gradually reduced in accordance with blood levels according to local immunosuppressive protocols until a recommended maintenance dose of about 2 to 6 mg/kg given in 2 divided doses is reached.
When Deximune is given with other immunosuppressants (e.g. with corticosteroids or as part of a triple or quadruple medicinal product therapy), lower doses (e.g. 3 to 6 mg/kg given in 2 divided doses for the initial treatment) may be used.
Bone marrow transplantation
The initial dose should be given on the day before transplantation. In most cases, a ciclosporine solution for infusion is preferred for this purpose. The recommended intravenous dose is 3 to 5 mg/kg/day. Infusion is continued at this dose level during the immediate post-transplant period of up to 2 weeks, before a change is made to oral maintenance therapy with Deximune at daily doses of about 12.5 mg/kg given in 2 divided doses.
Maintenance treatment should be continued for at least 3 months (and preferably for 6 months) before the dose is gradually decreased to zero by 1 year after transplantation.
If Deximune is used to initiate therapy, the recommended daily dose is 12.5 to 15 mg/kg given in 2 divided doses, starting on the day before transplantation.
Higher doses of Deximune, or the use of ciclosporine intravenous therapy, may be necessary in the presence of gastrointestinal disturbances which might decrease absorption.
In some patients, GVHD (Graft versus host disease) occurs after discontinuation of ciclosporin treatment, but usually responds favourably to re-introduction of therapy. In such cases an initial oral loading dose of 10 to 12.5 mg/kg should be given, followed by daily oral administration of the maintenance dose previously found to be satisfactory. Low doses of Deximune should be used to treat mild, chronic GVHD.
Non-transplantation indications
When using Deximune in any of the established non-transplantation indications, the following general rules should be adhered to:
Before initiation of treatment a reliable baseline level of renal function should be established by at least two measurements. The estimated glomerular filtration rate (eGFR) by the MDRD formula can be used for estimation of renal function in adults and an appropriate formula should be used to assess eGFR in paediatric patients. Since Deximune can impair renal function, it is necessary to assess renal function frequently. If eGFR decreases by more than 25% below baseline at more than one measurement, the dosage of Deximune should be reduced by 25 to 50%. If the eGFR decrease from baseline exceeds 35%, further reduction of the dose of Deximune should be considered. These recommendations apply even if the patient`s values still lie within the laboratory`s normal range. If dose reduction is not successful in improving eGFR within one month, Deximune treatment should be discontinued.
Regular monitoring of blood pressure is required.
The determination of bilirubin and parameters that assess hepatic function are required prior to starting therapy and close monitoring during treatment is recommended. Determinations of serum lipids, potassium, magnesium and uric acid are advisable before treatment and periodically during treatment.
Occasional monitoring of ciclosporin blood levels may be relevant in non-transplant indications, e.g. when Deximune is co-administered with substances that may interfere with the pharmacokinetics of ciclosporin, or in the event of unusual clinical response (e.g. lack of efficacy or increased drug intolerance such as renal dysfunction).
The normal route of administration is by mouth. If the concentrate for solution for infusion is used, careful consideration should be given to administering an adequate intravenous dose that corresponds to the oral dose. Consultation with a physician with experience of use of ciclosporin is recommended.
Except in patients with sight-threatening endogenous uveitis and in children with nephrotic syndrome, the total daily dose must never exceed 5 mg/kg.
For maintenance treatment the lowest effective and well tolerated dosage should be determined individually.
In patients in whom within a given time (for specific information see below) no adequate response is achieved or the effective dose is not compatible with the established safety guidelines, treatment with Deximune should be discontinued.

Endogenous uveitis
For inducing remission, initially 5 mg/kg/day orally given in 2 divided doses are recommended until remission of active uveal inflammation and improvement in visual acuity are achieved. In refractory cases, the dose can be increased to 7 mg/kg/day for a limited period.
To achieve initial remission, or to counteract inflammatory ocular attacks, systemic corticosteroid treatment with daily doses of 0.2 to 0.6 mg/kg prednisone or an equivalent may be added if Deximune alone does not control the situation sufficiently. After 3 months, the dose of corticosteroids may be tapered to the lowest effective dose.
For maintenance treatment, the dose should be slowly reduced to the lowest effective level. During the remission phases, this should not exceed 5 mg/kg/day.
Infectious causes of uveitis should be ruled out before immunosuppressants can be used.
Nephrotic syndrome
For inducing remission, the recommended daily dose is given in 2 divided oral doses.
If the renal function (except for proteinuria) is normal, the recommended daily dose is the following:
– adults: 5 mg/kg
– children: 6 mg/kg
In patients with impaired renal function, the initial dose should not exceed 2.5 mg/kg/day.
The combination of Deximune with low doses of oral corticosteroids is recommended if the effect of Deximune alone is not satisfactory, especially in steroid-resistant patients.
Time to improvement varies from 3 to 6 months depending on the type of glomerulopathy. If no improvement has been observed after this time to improvement period, Deximune therapy should be discontinued.
The doses need to be adjusted individually according to efficacy (proteinuria) and safety (primarily serum creatinine), but should not exceed 5 mg/kg/day in adults and 6 mg/kg/day in children.
For maintenance treatment, the dose should be slowly reduced to the lowest effective level.
Rheumatoid arthritis
For the first 6 weeks of treatment the recommended dose is 2.5 mg/kg/day orally given in 2 divided doses. If the effect is insufficient, the daily dose may then be increased gradually as tolerability permits, but should not exceed 4 mg/kg. To achieve full effectiveness, up to 12 weeks of Deximune therapy may be required.
For maintenance treatment the dose has to be titrated individually to the lowest effective level according to tolerability.
Deximune can be given in combination with low-dose corticosteroids and/or non-steroidal anti-inflammatory drugs (NSAIDs). Deximune can also be combined with low-dose weekly methotrexate in patients who have insufficient response to methotrexate alone, by using 2.5 mg/kg Deximune in 2 divided doses per day initially, with the option to increase the dose as tolerability permits.
Psoriasis
Deximune treatment should be initiated by physicians with experience in the diagnosis and treatment of psoriasis. Due to the variability of this condition, treatment must be individualised. For inducing remission, the recommended initial dose is 2.5 mg/kg/day orally given in 2 divided doses. If there is no improvement after 1 month, the daily dose may be gradually increased, but should not exceed 5 mg/kg. Treatment should be discontinued in patients in whom sufficient response of psoriatic lesions cannot be achieved within 6 weeks on 5 mg/kg/day, or in whom the effective dose is not compatible with the established safety guidelines.
Initial doses of 5 mg/kg/day are justified in patients whose condition requires rapid improvement. Once satisfactory response is achieved, Deximune may be discontinued and subsequent relapse managed with re-introduction of Deximune at the previous effective dose. In some patients, continuous maintenance therapy may be necessary.
For maintenance treatment, doses have to be titrated individually to the lowest effective level, and should not exceed 5 mg/kg/day given orally in two divided doses.
Atopic dermatitis
Deximune treatment should be initiated by physicians with experience in the diagnosis and treatment of atopic dermatitis. Due to the variability of this condition, treatment must be individualised. The recommended dose range in adults is 2.5 to 5 mg/kg/day given in 2 divided oral doses for a maximum of 8 weeks. If a starting dose of 2.5 mg/kg/day does not achieve a satisfactory response within 2 weeks, the daily dose may be rapidly increased to a maximum of 5 mg/kg. In very severe cases, rapid and adequate control of the disease is more likely to occur with a starting dose of 5 mg/kg/day. Once satisfactory response is achieved, the dose should be reduced gradually and, if possible, Deximune should be discontinued. Subsequent relapse may be managed with a further course of Deximune.
Switching between oral ciclosporin formulations
The switch from one oral ciclosporin formulation to another should be made under physician supervision, including monitoring of blood levels of ciclosporin for transplantation patients, to ensure that pre-conversion levels are attained.
Special populations
Patients with renal impairment
All indications
Ciclosporin undergoes minimal renal elimination and its pharmacokinetics are not extensively affected by renal impairment. However, due to its nephrotoxic potential, careful monitoring of renal function is recommended.
Non-transplantation indications
With the exception of patients being treated for nephrotic syndrome, patients with impaired renal function should not receive ciclosporin. In nephrotic syndrome patients with impaired renal function, the initial dose should not exceed 2.5 mg/kg/day.
Patients with hepatic impairment
Ciclosporin is extensively metabolised by the liver. An approximate 2- to 3-fold increase in ciclosporin exposure may be observed in patients with hepatic impairment. Dose reduction may be necessary in patients with severe liver impairment to maintain blood levels within the recommended target range and it is recommended that ciclosporin blood levels are monitored until stable levels are reached.
Paediatric population
Clinical studies have included children from 1 year of age. In several studies, paediatric patients required and tolerated higher doses of ciclosporin per kg body weight than those used in adults.
Use of Deximune in children for non-transplantation indications other than nephrotic syndrome cannot be recommended.
Elderly population (age 65 years and above)
Experience with Deximune in the elderly is limited.
In rheumatoid arthritis clinical trials with oral ciclosporin, patients aged 65 or older were more likely to develop systolic hypertension on therapy, and more likely to show serum creatinine rises ≥50% above the baseline after 3 to 4 months of therapy.
Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or medication and increased susceptibility for infections.
Method of administration
Oral use
Deximune capsules should be swallowed whole.

Prophylaxis of organ rejection in kidney, liver, heart allogenic transplants in conjunction with corticosteroids. May also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents.
Bone marrow transplantation.
Endogenous uveitis.
Severe psoriasis above age 16 that did not respond to other treatment.
Atopic dermatitis in adults only up to 8 weeks, for severe cases in which conventional therapy is ineffective or inappropriate.
Rheumatoid arthritis:
Severe cases in which standard treatments are ineffective or inappropriate.
Nephrotic syndrome type MCD (minimal change disease) in cases where conventional therapy has failed.

Hypersensitivity to the active substance or to any of the excipients.
Combination with products containing Hypericum perforatum (St John´s Wort).
Combination with medicines that are substrates for the multidrug efflux transporter P-glycoprotein or the organic anion transporter proteins (OATP) and for which elevated plasma concentrations are associated with serious and/or life-threatening events, e.g. bosentan, dabigatran etexilate and aliskiren.

For additional information, please contact the license holder.

For additional information, please contact the license holder.

For additional information, please contact the license holder.

For additional information, please contact the license holder.

For additional information, please contact the license holder.